Cell Impact (CI) Q3 2024 earnings summary

Executive summary

• Net sales for Q3 2024 were 5.6 MSEK, down 40% year-over-year; EBIT improved to -17.7 MSEK from -23.7 MSEK.

• Cost reduction programs have taken full effect, resulting in improved operating results despite lower revenue.

• The company is positioned for high-volume production and has confirmed sufficient financing for 2025.

Financial highlights

• Net sales for Q3 2024: 5.6 MSEK (9.3 MSEK Q3 2023); nine months: 35.1 MSEK (46.4 MSEK 2023).

• EBIT for Q3 2024: -17.7 MSEK (-23.7 MSEK Q3 2023); nine months: -59.4 MSEK (-80.7 MSEK 2023).

• Net result for Q3 2024: -17.9 MSEK (-24.9 MSEK Q3 2023); EPS: -0.03 SEK (-0.33 SEK Q3 2023).

• Cash flow from operations: 0.8 MSEK (-26.3 MSEK Q3 2023); cash at period end: 18.2 MSEK (35.1 MSEK 2023).

• Equity ratio at period end: 84% (75% Q3 2023).

Outlook and guidance

• Financing is assessed as sufficient for 2025, supported by recent capital injection from exercised warrants.

• Focus remains on scaling production capacity and cost efficiency to support future growth.